Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07021794 · ClinicalTrials.gov registry record · Phase 2
SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)
A Phase 2 study of Post-COVID / Long-COVID, sponsored by Nancy Klimas.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT07021794: Recruiting Phase 2 study of Post-COVID / Long-COVID, sponsored by Nancy Klimas.
NCT07021794 is a Phase 2 study of Post-COVID / Long-COVID that is actively recruiting participants, run by Nancy Klimas. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07021794, a Phase 2 study of Post-COVID / Long-COVID, is actively recruiting participants, sponsored by Nancy Klimas.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This placebo-controlled, randomized, blinded, two-arm phase II study will test the safety and potential efficacy of the targeted mAb, Sipavibart (formerly AZD3152) in patients with Long COVID.
Primary Outcome
Comprehensive Symptom Burden Index (CSBI) total scores will serve as a composite outcome measure derived from eight PROMIS domains to capture overall symptom burden. Scores will be calculated at baseline and Week 12. Efficacy will be determined by the proportion of participants classified as IMPROVED, defined as having a ≥4.5-point increase in CSBI from baseline, a threshold representing moderate and clinically meaningful improvement.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Sipavibart
Study Locations (1)
Florida
- Nova Southeastern University - Fort Lauderdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-06-16 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What NCT07021794 shows while recruiting
NCT07021794 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Post-COVID / Long-COVID appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07021794 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07021794 about?
NCT07021794 is a clinical study titled "SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)". This placebo-controlled, randomized, blinded, two-arm phase II study will test the safety and potential efficacy of the targeted mAb, Sipavibart (formerly AZD3152) in patients with Long COVID.
What is the current status of trial NCT07021794?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-06-16. Estimated completion is 2026-12-31.
What conditions does trial NCT07021794 study?
This clinical trial studies the following conditions: Post-COVID / Long-COVID.
What interventions are being tested in trial NCT07021794?
The interventions under investigation include: Placebo (DRUG), Sipavibart (BIOLOGICAL).
Who is sponsoring clinical trial NCT07021794?
This trial is sponsored by Nancy Klimas, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07021794 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07021794's enrollment target sits among peer trials
100 672nd of 2000 higher than 1,264 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI